Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase

BACKGROUND: Despite overexpression of the ErbB (EGFR/HER2/ErbB3/ErbB4) family in castration-resistant prostate cancer (CRPC), some inhibitors of this family, including the dual EGFR/HER2 inhibitor lapatinib, failed in Phase II clinical trials. Hence, we investigated mechanisms of lapatinib resistanc...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Cancer
Autori principali: Jathal, Maitreyee K., Steele, Thomas M., Siddiqui, Salma, Mooso, Benjamin A., D’Abronzo, Leandro S., Drake, Christiana M., Whang, Young E., Ghosh, Paramita M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6738116/
https://ncbi.nlm.nih.gov/pubmed/31209328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0496-4
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi